Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 14,334 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 14,334 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the sale, the chief executive officer now directly owns 589,552 shares of the company’s stock, valued at $26,294,019.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Twist Bioscience Stock Down 0.3 %

Twist Bioscience stock opened at $45.40 on Friday. Twist Bioscience Co. has a 52 week low of $15.85 and a 52 week high of $60.90. The firm’s 50-day simple moving average is $43.69 and its 200 day simple moving average is $45.64. The firm has a market capitalization of $2.66 billion, a PE ratio of -11.88 and a beta of 1.78.

Analysts Set New Price Targets

TWST has been the subject of several analyst reports. Evercore ISI increased their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Barclays cut their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TWST. BNP Paribas Financial Markets increased its position in Twist Bioscience by 34.8% during the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after purchasing an additional 44,349 shares in the last quarter. SageView Advisory Group LLC acquired a new stake in Twist Bioscience during the 1st quarter worth approximately $1,144,000. Susquehanna Fundamental Investments LLC acquired a new stake in Twist Bioscience during the 1st quarter worth approximately $300,000. Sei Investments Co. increased its position in Twist Bioscience by 32.7% during the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after purchasing an additional 55,124 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC increased its position in Twist Bioscience by 38.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after purchasing an additional 37,376 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.